Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis

Correspondence to the original research entitled “Effects of ranibizumab and zoledronic acid on endometriosis in a rat model” published by Ozdemir et al.

Ureyen Ozdemir E, Adali E, Islimye Taskin M, Yavasoglu A, Aktug H, Oltulu F et al (2021) Effects of ranibizumab and zoledronic acid on endometriosis in a rat model. Arch Gynecol Obstet. https://doi.org/10.1007/s00404-021-06104-9 Ferro Desideri L, Barra F, Ferrero S, Traverso CE, Nicolo M (2019) Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration. Expert Opin Biol Ther 19(8):735–751 Weinstein O, Abu Tailakh M, Lifshitz T, Novack V, Levy J (2020) Intravitreal bevacizumab treatment for neovascular age-related macular degeneration and thromboembolic events. Eur J Ophthalmol 30(1):66–71 Nicolo M, Morlacchi A, Cappelli F, Ferro Desideri L, Colombo V, Musetti D et al (2020) Real-life data in the treatment of neovascular age-related macular degeneration: results from the imaculaweb registry evaluated in a single italian medical retina center. Ophthalmologica 243(6):453–460 Ferro Desideri L, Cutolo CA, Traverso CE, Nicolo M (2021) Razumab—the role of biosimilars for the treatment of retinal diseases. Drugs Today (Barcelona) 57(8):499–505 Chen HX, Cleck JN (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465–477 Oryan A, Sahvieh S (2021) Effects of bisphosphonates on osteoporosis: focus on zoledronate. Life Sci 264:118681 Barra F, Scala C, Mais V, Guerriero S, Ferrero S (2018) Investigational drugs for the treatment of endometriosis, an update on recent developments. Expert Opin Investig Drugs 27(5):445–458 La Rosa VL, De Franciscis P, Barra F, Schiattarella A, Torok P, Shah M et al (2020) Quality of life in women with endometriosis: a narrative overview. Minerva Med 111(1):68–78 Funding This paper is not funded. Author information Authors and Affiliations Contributions FB: DATA collection and manuscript writing; LFD: Data collection and manuscript writing; SF: manuscript editing; CG: project administration; CET: manuscript editing and revision; MN: project development and manuscript revision. Corresponding author Ethics declarations Conflict of interest Fabio Barra, Lorenzo Ferro Desideri, Simone Ferrero, Claudio Gustavino, Carlo Enrico Traverso, and Massimo Nicolò declare that they have no conflict of interest to declare. Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors. Additional information Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Rights and permissions About this article Cite this article Barra, F., Ferro Desideri, L., Gustavino, C. et al. Concerns on ranibizumab and zoledronic acid safety for experimentally treating women with endometriosis. Arch Gynecol Obstet 306, 569–570 (2022). https://doi.org/10.1007/s00404-021-06390-3 Received: Accepted: Published: Version of record: Issue date: DOI: https://doi.org/10.1007/s00404-021-06390-3